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 effectiveness for lowering IOP compared with latanoprost 0.005% (w/v) and travo-
prost 0.004% (w/v).
PSS7
A LiterAture review on CoSt-effeCtiveneSS of treAtmentS for wet 
Age-reLAted mACuLAre degenerAtion
Ying X., Feng S., Lu J., Qi F.
Fudan University, China, Shanghai, China
Objectives: To compare the cost-effectiveness for different therapies to Wet Age-
Related Maculare Degeneration (wAMD) MethOds: Literature Review: Several 
Database, such as Pubmed, Web of Science, Elsevier, Medline were searched using 
16 codes. We applied inclusion criteria to screen the literature. Randomized con-
trolled trials (RCTs), Controlled Clinical Trials (CCTs), and Controlled Before-and-
After studies were selected. This study focus on three commonly interventions to 
wAMD: Best Supportive Case (BSC), PhotoDynamic Therapy (PDT), and Ranibizumab 
therapy. Cost-effectiveness analysis (CEA), cost-utility analysis (CUA), and incremen-
tal analysis were conducted. Results: Compare with BSC and PDT, Ranibizumab 
therapy was more effective in wAMD treatment in different countries. From social 
perspective, Ranibizumab therapy was also more cost-effectiveness than BAC and 
PDT either in 5 years or in 10 years. However, from third-payer perspective, incre-
mental cost-effectiveness ratio (ICER) between Ranibizumab and BSC, Ranibizumab 
and PDT, varied in different countries. Frequency and duration of Ranibizumab 
usage may be key determinants of ICER. cOnclusiOns: Ranibizumab therapy have 
better clinical effect than BSC and PDT in wAMD treatment. Ranibizumab is also 
more cost-effectiveness than BSC and PDT from social perspective in long term. 
It may be related to the highly indirect cost of wAMB. However, from third-payer 
perspective, Ranibizumab may be good cost-effectiveness. Price and quantity of 
Ranibizumab in therapy influenced its cost-effectiveness. More research based on 
varied price and different drug usage in Ranibizumab therapy should be conducted 
before it were paid.
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eConomiC evALuAtion of BevACizumAB verSuS rAniBizumAB in 
neovASCuLAr Age-reLAted mACuLAr degenerAtion in ChinA
Li H.1, Li X.2, Xie F.3
1China Pharmaceutical University, Nanjing, China, 2People’s Hospital, Peking University, Beijing, 
China, 3McMaster University, Hamilton, ON, Canada
Objectives: To evaluate the cost-effectiveness of the off-label used bevacizumab 
versus ranibizumab for patients with neovascular age-related macular degenera-
tion (AMD) in China. MethOds: Two different Markov models were used separately 
to compare cost per quality-adjusted life year (QALY) of four strategies defined by 
drug (bevacizumab or ranibizumab) and dosing regimen (monthly or as needed) 
in patients with neovascular AMD in China’s health care system. The VA Range 
model defines the health states using visual acuity (VA), while the VA Change model 
defines the health states according to the degree of VA changes from the time when 
entering the model. Both models used a life time horizon with a cycle length of 3 
months. Clinical data used in the models primarily came from the Comparison of 
AMD Treatment Trial (CATT), while the costs came from the financial department of 
a tertiary hospital in Beijing. Results: In the base-case analyses, the bevacizumab 
as needed strategy had slightly lower QALYs (17.479 QALYs and 15.917 QALYs in 
the VA Range model and the VA Change model, respectively) but at much lower 
costs (CN¥88,341 and CN¥79,967 in the VA Range model and the VA Change model, 
respectively) compared with the other three strategies. In probabilistic sensitivity 
analyses in both models, the probabilities of bevacizumab strategies being more 
cost-effective than ranibizumab strategies exceeded 99% if the willingness-to-pay 
(WTP) threshold for a QALY was less than CN¥120,000. When the threshold was less 
than CN¥90,000 per QALY, bevacizumab as needed was the most cost-effective alter-
native. cOnclusiOns: The bevacizumab as needed strategy was the most cost-
effective strategy compared with the ranibizumab strategies in treating patients 
with neovascular AMD, if the WTP threshold is below CN¥90,000 per QALY in China. 
This much cheaper treatment can substantially reduce the burden to the Chinese 
aging society.
PSS9
CoSt utiLity AnALySiS of uStekinumAB for the treAtment of 
moderAte to Severe ChroniC PLAque PSoriASiS in thAiLAnd
Tangwongsiri D.1, Leartsakulpanitch J.2
1Janssen-Cilag (Thailand) Limited, Bangkok, Thailand, 2Janssen Asia Pacific, Singapore
Objectives: To evaluate the cost-utility of ustekinumab versus infliximab and 
etanercept, the only biologic agents available for psoriasis in Thailand, among 
adults with moderate-to-severe plaque psoriasis who fail to respond systemic 
therapies and meet criteria based on the biologic guideline for psoriasis in 
Thailand. MethOds: The published ‘York psoriasis model’ was modified based 
on the current treatment algorithm and criteria of biologics use in Thai psoriasis 
guideline. Short-term trial efficacy data (PASI response) from a published network 
meta-analysis of RCT was used to model the response of patients to initial treat-
ment. Beyond the initial period, the model extrapolated results up to 10 years with 
annual risk of treatment withdrawal. The DLQI scores from ustekinumab trials were 
transposed into utility gain (EQ5D) and applied to PASI response level regardless of 
the treatment received. Both direct medical cost and non-medical cost including 
biologic acquisition, monitoring lab tests, outpatient visit, and traveling expense 
were calculated. The amount of resource consumption was estimated by experts’ 
opinions and literatures. Cost and outcomes were discounted at 3%. One-way 
and probabilistic sensitivity analysis was conducted to assess the model robust-
ness. Results: Over the 10-year time horizon, ustekinumab showed the lowest 
mean annual cost of 507,502 baht followed by etanercept (582,881 baht) and inflixi-
mab (585,462 baht) respectively. The mean QALY gain of ustekinumab was higher 
than etanercept (0.1448 vs. 0.1392) but lower than infliximab (0.1448 vs. 0.1564). 
Considering the cost-utility ratio, ustekinumab was dominant compared to etaner-
Preschool children with dental caries is associated with high treatment costs and 
the number of cavities play an important role in determination of costs. Therefore, 
preschool children should pay attention to oral hygiene and form good habits to 
prevent dental caries.
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Burden of wet Age-reLAted mACuLAr degenerAtion in ChinA
Zhang Y.1, Hu S.2, Chang J.3
1shanghai Institution of Technolocy, Shanghai, China, 2Shanghai Bureau of Health, Shanghai, 
China, 3Beijing Novartis Pharma Co., Ltd, Beijing, China
Objectives: To explore the burden of wet age-related macular degeneration 
(WAMD) in China. MethOds: Multi-center, retrospective and cross-sectional inves-
tigation was adopted. Beijing, Chengdu, Guangzhou and Shanghai were selected 
as sample cities, and several hospitals were involved in each city. Patients were 
selected according to inclusive and exclusive criteria, and they were divided into 5 
groups, i.e., photodynamic therapy (PDT), photocoagulation therapy, surgery therapy, 
joint therapy and support therapy groups. Direct cost, indirect cost and burden of 
disease (BOD) were studied. Results: 417 eligible patients were acquired, males 
and females accounted for 51.32% and 48.68% respectively. Burden of WAMD for 
per eye per year was 4857 USD. Burden of WAMD of whole disease course for each 
eye was 33999 USD. The proportion of direct medical cost in BOD was only 26.35%, 
however, that of indirect cost reached 68.58%. cOnclusiOns: The burden of 
WAMD is relatively high in China, it should be paid more attention by stakehold-
ers. Although new diagnostic and therapeutic methods may raise direct medical 
cost, they may reduce total burden of  WAMD more, which shows the advantage for 
new technologies. WAMD guideline will be beneficial to both patients and direct 
medical cost management. Targeting young patients as a priority of intervention 
will help to reduce total social burden of  WAMD.
PSS5
CoSt-effeCtiveneSS AnALySiS of LAtAnoProSt ComPAred with 
dorzoLAmide/timoLoL fixed ComBinAtion for the treAtment of oPen-
AngLe gLAuComA And oCuLAr hyPertenSion PAtientS in koreA
Lee Y., Park D.J., Ko S.K.
Pfizer Pharmaceuticals Korea Ltd., Seoul, South Korea
Objectives: Glaucoma is a major cause of visual impairment and a chronic dis-
ease requiring treatment for lifetime. Management of intraocular pressure (IOP) 
is the main focus of treatment, and many pharmacological treatment agents are 
recommended and available in Korea. This study was conducted to facilitate effi-
cient allocation of limited resources amongst various pharmacological agents. The 
objective of this study was to evaluate costs and effectiveness of two most com-
monly used drugs in Korea which are latanoprost and dorzolamide/timolol fixed 
combination. MethOds: A decision analytic model was developed from a payer 
perspective to evaluate clinical effectiveness, costs and utility values of latanoprost 
and dorzolamide/timolol fixed combination. The model was constructed based on a 
one-month cycle with a time horizon of one year. The treatment success to meas-
ure effectiveness was defined as achieving a ≥ 20% reduction IOP from baseline. 
Costs of medication, diagnostic fees, physician and pharmacy visitation fees, and 
surgery fees were included in the study. Utility values according to the severity 
of glaucoma were also incorporated in the model. Treatment success and failure 
rates as well as utility for each health state were obtained from previously pub-
lished literature and local market analysis data. Cost information was obtained 
from Korea-specific data sources. The result of this study was expressed in an 
incremental cost-effectiveness ratio (ICER). One-way sensitivity analysis was con-
ducted to evaluate different clinical parameters. Results: The final effectiveness 
values for latanoprost and dorzolamide/timolol fixed combination were 0.9098 and 
0.9089 in quality-adjusted life year (QALY), and the final costs were 550,737 KRW 
and 534,789 KRW respectively. Latanoprost displayed an ICER of 17,500,246 KRW/
QALY compared to dorzolamide/timolol fixed combination. cOnclusiOns: Under 
the currently implied ICER threshold in Korea, latanoprost can be interpreted as a 
cost-effective treatment option compared to dorzolamide/timolol fixed combination 
on the treatment of glaucoma.
PSS6
A ProSPeCtive PhArmACoeConomiC Study of BiLAterAL 
ProStAgLAndin/ ProStAmide therAPy for Lowering intrAoCuLAr 
PreSSure (ioP) in the PAtientS in South indiA
Addanki D.
Raghavendra Institute of Pharmaceutical Education and Research, Anantapur, India
Objectives: To determine monthly cost and cost effectiveness of bilateral prosta-
glandin/ prostamide therapy for lowering intraocular pressure (IOP) in patients tak-
ing bimatoprost (0.03%), latanoprost (0.005%), or travoprost (0.004%). MethOds: 
This prospective pharmacoeconomic study evaluated the direct cost and cost effec-
tiveness of prostaglandin/prostamide therapy for reduction of IOP in patients with 
glaucoma or ocular hypertension. Drops in five new 2.5-mL bottles were counted 
and then averaged for each drug. Average retail price was determined by surveys 
of pharmacies. Drop count, average retail price, average wholesale price, and IOP 
reduction data were used to compute annual cost, and cost effectiveness (annual 
cost-per-mm Hg of IOP reduction) of the three drugs. Results: Drops per 2.5-mL 
bottle averaged 113 for bimatoprost 0.03% (w/v), 84 for latanoprost 0.005% (w/v), and 
83 for travoprost 0.004% (w/v). Average retail cost (2005) per bottle was INR.3,080 
for bimatoprost 0.03% (w/v), INR.2,715 for latanoprost 0.005% (w/v), and INR.2,920 
for travoprost 0.004% (w/v). The monthly retail cost of bilateral therapy was 
INR.1,668 for bimatoprost 0.03% (w/v), INR.1,970 for latanoprost 0.005% (w/v), and 
INR.2,167 for travoprost 0.004% (w/v). Cost effectiveness ranges were INR.2,508 
to INR.2,860 per mm Hg reduction in IOP per year for bimatoprost, 0.03% (w/v), 
INR.2,948 to INR.3,960 per mm Hg for latanoprost 0.005% (w/v), and INR.3,256 to 
INR.3,696 per mm Hg for travoprost 0.004% (w/v). cOnclusiOns: Bimatoprost 
0.03% (w/v) had the lowest monthly and annual costs and the greatest cost 
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Hispanic (55.0%), enrolled in fee-for-service program (83.1%) and from an urban 
region (60.1%). OM-related antibiotic prescription claims decreased from 137,557 
in 2008 ($5,281,040) to 65,697 in 2011 ($2,010,391). The mean cost per prescription 
decreased significantly from $38.39 in 2008 to $30.60 in 2011 (p< 0.01). The most 
frequently used category of OM-related antibiotics was penicillins (215,654 claims). 
Amoxicillin was the most frequently prescribed OM-related antibiotic (48.2%), fol-
lowed by cefdinir (21.0%). However, the total outpatient prescription cost was highest 
for cefdinir ($5,736,640), followed by amoxicillin-clavulanate ($2,798,234), amoxi-
cillin ($1,914,929), azithromycin ($1,298,427), cefuroxime ($49,191), clarithromycin 
($42,959), cefpodoxime ($19,685) and ceftriaxone ($5,792). Higher age, Asian race/ 
ethnicity, female gender, fee-for-service program enrollment, Texas region, acute 
OM, amoxicillin-clavulanate, and cephalosporins were significant predictors 
(p< 0.01) of high cost prescriptions. cOnclusiOns: Prescription claims and expen-
ditures for selected OM-related antibiotics declined between 2008 and 2011 in the 
Texas Medicaid pediatric population.
SyStemiC diSorderS/ConditionS – Clinical outcomes Studies
PSy1
SeCond generAtion AzoLeS for ProPhyLAxiS AgAinSt invASive 
fungAL infeCtion: iS voriConAzoLe equivALent to PoSAConAzoLe in 
hAemAtoLogy PAtientS?
Zhao F.L., Wong A.M., Ryan S., Struwig V.A.
Pfizer Australia, West Ryde, Australia
Objectives: No randomised controlled trial has compared voriconazole and posa-
conazole directly for prophylaxis against invasive fungal infections (IFI) in high risk 
haematology patients. We performed a systematic review and indirect comparison 
of voriconazole versus posaconazole using itraconazole/fluconazole as the common 
comparator. MethOds: Systematic review of full body of evidence including ran-
domised controlled trials and non-randomised studies. Adjusted indirect meta-anal-
ysis was performed using Bucher method. Non-randomised studies provide evidence 
for direct comparison between voriconazole and posaconazole. Results: A total of 
4 RCTs and 4 non-randomised studies that evaluated voriconazole or posaconazole 
were included. In these studies, two risk groups were identified on the basis of disease 
type – the haemopoetic stem cell transplant (HSCT) at risk of GVHD population, and 
acute myelogenous leukaemia or myelodysplastic syndrome (AML/MDS) population. 
The indirect estimates of risk differences (RD) were not statistically significantly dif-
ferent from 0.0; therefore indicating that voriconazole is not worse than posaconazole 
in terms of the incidence of proven or probable IFI [RD (95% CI): 0.00 (-0.06, 0.06) in 
HSCT/GVHD; 0.04 (-0.06, 0.14) in AML/MDS] and all-cause mortality rates [RD (95% 
CI): -0.00 (-0.07, 0.06) in HSCT/GVHD; 0.03 (-0.09, 0.16) in AML/MDS]. Results should be 
interpreted with caution due to heterogeneity between the risk levels of patient popu-
lations. However, the robustness of the indirect comparisons can be supported by the 
four direct non-randomised studies which consistently demonstrated similar efficacy 
of voriconazole and posaconazole and superior efficacy of voriconazole over itracona-
zole and fluconazole based on the incidence of breakthrough IFI. cOnclusiOns: 
The clinical evidence presented in the direct and indirect comparisons consistently 
demonstrate that there are no statistically significant differences between voricona-
zole and posaconazole in terms of efficacy outcomes. Voriconazole offers an alterna-
tive option to posaconazole, which is the only therapy currently reimbursed on the 
Australian Pharmaceutical Benefits Schedule for prophylaxis of IFI.
PSy2
interChAngeABiLity Study of muLtiSourCe PArACetAmoL 500mg 
tABLetS, ProduCed in mongoLiA
Ichinkhorloo T.
Fourth Health Sector Development Project, Ulaanbaatar, Mongolia
Objectives: To define interchangeability of locally produced Paracetamol 
(Acetaminophen INN), 500mg tablets. MethOds: For this purpose Paracetamol 
500mg tablets produced by 7 local manufacturers were tested. As a comparator 
product was used Panadol 500mg, produced by GlaxoSmithKline. Bioequivalence 
testing was done according to the WHO guideline, Multisource (generic) pharma-
ceutical products: guidelines on registration requirements to establish interchange-
ability, WHO Technical Report Series, No.937, 2006. Based on Biopharmaceutics 
Classification System Paracetamol tablets bioequilvalency testing was done in vitro 
through determination of dissolution. Results: In each media of pH 1.2, 4.5 and 
6.8 were tested 12 unit samples. All samples were dissolved in three media in not 
less than 85% of the labelled amount of the paracetamol in 15 minutes. According to 
the questionnaire, all manufacturers producing Paracetamol tablets answered that 
the formulation of dosage form was considered the attribute of active pharmaceu-
tical ingredient and excipients and used machinery’s specification. As criteria for 
choosing the formulation, manufacturers were used pharmacopoeial monograph, 
stability study data and dissolution results. Mongolian manufacturer’s Paracetamol 
formulations not contain excipients such as sodium bicarbonate, which is fasten-
ing the drug absorption. Three manufacturers use Povidone as a binder, same like 
comparator product. Most formulations contain Talc and Magnesium stearate as 
a lubricant mix, when comparator contains Stearic acid and Talc. All formulations 
contain starch and cellulose, their derivates. cOnclusiOns: Paracetamol 500mg 
tablets produced by all 7 local manufacturers: LM1, LM2, LM3, LM4, LM5, LM6 and 
LM7 have dissolution more than 85% in 15 minutes in each of three media. Therefore 
the dissolution profile comparison with an f2 test is unnecessary [4]. Samples: LM1, 
LM2, LM3, LM4, LM5, LM6 and LM7 are bioequivalent and could be interchangeable 
with comparator pharmaceutical product.
PSy3
CLiniCAL effiCACy of the PoLyherBAL AyurvediC mediCine in the 
mAnAgement of overweight
Sasikumar U.H.1, Acharya S.1, Reddy K.2, Nagappa A.N.3
cept and infliximab showed the ICER of 6,719,775 baht/QALY compared to usteki-
numab. The probability of cost-effective at threshold of 120,000 baht/QALY remained 
in favor of ustekinumab at 72.60% and presented at 13.60% for both etanercept 
and infliximab. cOnclusiOns: Ustekinumab seems to be more cost-effective than 
etanercept and infliximab for patients with moderate-to-severe plaque psoriasis 
following biologic treatment guideline for psoriasis in Thailand.
SenSory SyStemS diSorderS – Patient-reported outcomes & Patient Prefer-
ence Studies
PSS10
AdherenCe, PrediCting fACtorS And SAtiSfACtion of PAtientS on 
gLAuComA therAPy: findingS from A CroSS-SeCtionAL Study in koreA
Park K.H.1, Cha J.H.2
1Seoul National University College of Medicine, Seoul, South Korea, 2Pfizer Pharmaceuticals Korea 
Ltd., Seoul, South Korea
Objectives: The aim of the study was to identify adherence and predicting fac-
tors for non-adherence and to assess the association of adherence with patient 
satisfaction of glaucoma therapy. MethOds: The study population included 1,046 
glaucoma outpatients with less than two years of drug use recruited at15 eye clinics 
from March to November 2013. All patients completed a self-administered question-
naire asking about their daily use of glaucoma medications to estimate adherence 
and patients’ baseline characteristics to examine predicting factors for non-adher-
ence. Adherence was defined as patients administering the drug for ≥ 90% of pre-
scribed days. Patient satisfaction was also measured using the 14-item Treatment 
Satisfaction Questionnaire for Medication (TSQM) questionnaire which provided 
scores on four sub-scales: medication effectiveness, side effects, convenience and 
global satisfaction. The scores on TSQM are ranged 0 to 100 where higher scores indi-
cate better satisfaction. Results: Of 1,046 patients, 71.1%showed to be adherent to 
their glaucoma therapy while 28.9% accounting for 298 number of patients remained 
non-adherent. The predicting factors for non-adherence were found to be patients 
age < 65 years, and employed (p< 0.05). Non-adherent patients showed less satisfac-
tory to treatment than adherent patients as displayed by relatively lower scores in 
all sub-scales on TSQM. In the scores on the TSQM, the largest difference between 
non-adherent and adherent patients was observed on medication effectiveness 
(26.07±12.21 vs. 59.21±14.27, p< 0.001) and the smallest difference was detected in 
side effects (89.53±18.00 vs. 90.50±16.46, p= 0.405). cOnclusiOns: About one third 
of the study population were non-adherent, and age and employment status were 
shown to influence non-adherence. Patient satisfaction was significantly associ-
ated with adherence given the lower scores on TSQM in non-adherent patients. 
Thus, these findings should be taken into account in decision making process for 
glaucoma treatment.
PSS12
utiLity vALueS Among myoPiC PAtientS in mAinLAnd ChinA
Li S.
Shandong University, Jinan, China
Objectives: To elicit utility values of adult myopic patients in mainland 
China. MethOds: A valid sample of 442 myopia patients (spherical equivalent at 
least −0.5 D) aged 17–44 years, who were scheduled to undergo refractive surgery, 
were recruited. Information on time trade-off (TTO, years of life willing to sacrifice 
for treatment of myopia) and standard gamble (SG) for blindness (risk of blindness 
from therapy, willing to sacrifice for treatment of myopia) utility values, socio-
demographic and clinical data were obtained. Results: The mean utility values 
based on TTO and SG were 0.96±0.05 (95% confidence interval (CI) 0.95–0.96, median 
0.98) and 0.93±0.09 (95% CI 0.92–0.94, median 0.97), respectively. Myopic patients 
using contact lens had significantly higher TTO utility values than those wearing 
glasses (P< 0.001). There was no significant difference in the TTO and SG utility val-
ues by age, gender, occupation, educational levels, residence, reasons for refractive 
surgery, severities and duration of myopia (P> 0.05). cOnclusiOns: The TTO and SG 
produce similar mean utility values, but there is poor agreement between results for 
individuals from the two methods. Utility values associated with myopic patients 
obtained in this study or reported in the literature appear to be higher than those 
obtained for other ophthalmic conditions.
SenSory SyStemS diSorderS – health Care use & Policy Studies
PSS13
PreSCriBing PAtternS And exPenditureS for otitiS mediA-reLAted 
AntiBiotiCS for ChiLdren in the texAS mediCAid ProgrAm
Ma X., Lawson K.A., Richards K.M.
The University of Texas at Austin, Austin, TX, USA
Objectives: To determine the prescribing patterns and expenditures for otitis 
media (OM)-related antibiotics in the Texas Medicaid pediatric population, and 
identify the demographic and antibiotic-related factors associated with expen-
sive prescriptions for OM-related antibiotics. MethOds: This retrospective study 
used Texas Medicaid outpatient medical and prescription claims data for children 
younger than 13 years old with a diagnosis of OM (ICD-9: 381.0-382.0) and claims 
for OM-related antibiotics from January 2008 to December 2011. OM-related anti-
biotics were selected based on the guidelines proposed by the American Academy 
of Pediatrics and the American Academy of Family Physicians in 2004, and were 
classified into three categories: cephalosporins, macrolides and penicillins (amox-
icillin, amoxicillin-clavulanate). The total number (proportion) of prescriptions 
and costs were compared across selected antibiotics and categories. Generalized 
linear model was used to evaluate potential factors associated with expensive 
prescriptions. Results: 335,638 children with a mean age of 3.9 (SD= 3.2) years 
were included. The majority were boys (52.1%), younger than 3 years old (55.0%), 
